BeNeLuxBelgiumNetherlandsLuxembourg

ActoGeniX: 20 million euros round

16.03.2007

Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.

BeNeLuxBelgiumNetherlandsLuxembourg

04.04.2011

An industry based on renewable resources is not to be had for free. Switching from petroleum-driven large-scale industry to a biobased economy will cost both time and money. But the question is – who will pay for it? Can you...

BeNeLuxBelgiumNetherlandsLuxembourg

18.03.2011

Rotterdam – Dutch microarray diagnostics specialist Skyline Diagnostics BV has launched a unique microarray for subtyping patients with the most deadly blood cancer AML into different risk groups. AMLprofiler™ replaces current...

BeNeLuxBelgiumNetherlandsLuxembourg

17.03.2011

Leiden – Crucell N.V. has signed an agreement with Pepscan Therapeutics to use its protein mimicry technology to develop vaccines to treat undisclosed infectious diseases. Pepscan’s Chemical Linkage of Peptides onto Scaffolds...

BeNeLuxBelgiumNetherlandsLuxembourg

01.03.2011

Leiden/San Diego – Bad news for the Dutch Pharming Group and its partner Santarus Inc, who wants to market the heriditary angioedema treatment Rhucin (INN conestat alfa) in North America – the FDA said on Monday, that the...

BeNeLuxBelgiumNetherlandsLuxembourg

24.02.2011

Amsterdam – Dutch molecular diagnostics company Agendia NV has received the green light to use its MammaPrint breast cancer recurrence assay on Agilent microarray scanners and Agilent Bioanalyzers. The additional clearance will...

BeNeLuxBelgiumNetherlandsLuxembourg

06.02.2011

Leiden – Dutch OctoPlus N.V. has successfully completed an equity raising of EUR4m through a private placement of ordinary shares with new and existing investors, including a participation by its CEO elect, Jan Egberts. The...

BeNeLuxBelgiumNetherlandsLuxembourg

06.02.2011

Mechelen – Galapagos NV has completed first-in-human trials with its compound GLPG0555 in healthy volunteers as part of an arthritis alliance with Glaxo­SmithKline. The company also initiated Phase I testing for a second...

BeNeLuxBelgiumNetherlandsLuxembourg

06.02.2011

Rotterdam – Biopharmaceutical company arGEN-X BV has entered into an alliance that will generate monoclonal antibody candidates against diverse functional sites in targets from Eli Lilly and Co. Founded in 2008, the Dutch biotech...

BeNeLuxBelgiumNetherlandsLuxembourg

05.02.2011

Brussels – The European Biotechnology Network's "Biotechnology Funding Hub" service, which was launched last year, will be examining the US in this quarter, taking a close look at how companies can combine US and EC funding to...

Displaying results 51 to 60 out of 304

< Previous 51-60 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/5/article/actogenix-20-million-euros-round.html

Product of the week

Products

Events

All Events

Current issue

All issues